2025-04-24 04:53:58 pm | Source: PR Agency
Morepen Labs launches 4 new products -“Ticapen, UdoFix, LycoMore, Acifix”
Morepen Laboratories is pleased to announce the launch of four new products—Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing its commitment to offer innovative latest products marking an another milestone reinforcing the doctor and patient trust. These new launches reflect our unwavering focus on research-led innovation, clinical excellence, and affordable healthcare access, addressing critical needs in cardiology, hepatology, nutrition, and diabetology.
This strategic expansion reinforces Morepen’s commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.
As India’s #1 exporter of APIs for six globally used molecules—Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine—Morepen has a presence in 82 countries, backed by an annual API manufacturing capacity of 144 metric tons. Its integrated capabilities across the pharmaceutical value chain give it a unique competitive edge in both regulated and emerging markets like the US, Europe, Japan, China, and Russia. With a current formulation business size of approximately Rs.325 crore, the company is now accelerating toward a Rs.1,000 crore target over the next five years—driven by deeper market penetration, an expanded field force, and a growing portfolio of cost-efficient, globally compliant therapies.
Above views are of the author and not of the website kindly read disclaimer
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Rooted in Balance: A Day in the Life of an Ayurvedic...
Toe-tally Trendy: The Rise of Toe Rings in Modern Fa...
Hockey India names core probable group for senior me...
Five more Indians progress to semis at Asian U-15 & ...
Vardhaan Puri: Acting is like therapy
Kajol to Samantha: Celebs shower birthday wishes on ...
FUJIFILM India Partners with Spectra Logic to Delive...
NSE IT Index Surges 4.3% ? What's Next for Tech Stoc...
Mid-sized GCCs to set up 120 centres, create 40,000 ...
Nifty Wrap : The index opened on a muted note, and t...
